1 insider bought €33k of shares over the last 90 days, the latest by 김기옥, filed 12 Aug 2026.
Genolution Inc.: what insiders have been doing
Genolution Inc. belongs to the Health Care sector. Filings by its managers are published through DART (FSS). The last twelve months, up to 1 November 2026, brought 25 filings signed by 7 insiders.
Open-market activity splits into 15 purchases totalling €86k and 3 sales; 4 insiders sit on the buying side and 1 insider on the selling side. The totals exclude 15 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 2 chief executives, 1 board member and 1 senior executive among the declarants. The largest single trade was a purchase of €30k by 김민이, published on 18 March 2026, equal to 0.20% of the market capitalisation.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 25 filings here. Since 2021, the database holds 26 purchases and 3 sales by insiders of the company.
The last insider purchase was made public on 12 August 2026, 89 days ago. Filings reach the DART (FSS) feed a median of 4 days after the trade. Until a filing is published, the market cannot know about the trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -3.7%Entry ₩1,790 · Close 30 Oct 2026 ₩1,724
- +4.7%Entry ₩1,647 · Close 30 Oct 2026 ₩1,724
- -3.7%Entry ₩1,790 · Close 30 Oct 2026 ₩1,724
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 36,938 sharesShareKRXDART:20260812000082Canonical exit: 10 Nov 2026 (T+90)
- Other0DART
- 1,112,740 sharesShareKRXDART:20260804000118Canonical exit: 2 Nov 2026 (T+90)
- 18,136 sharesShareKRXDART:20260722000082Canonical exit: 20 Oct 2026 (T+90)
- KRXDART:20260701000043
- ShareKRXDART:20260701000042
- 4,360 sharesShareKRXDART:20260630000108Canonical exit: 28 Sept 2026 (T+90)
- 41,827 sharesShareKRXDART:20260630000113Canonical exit: 28 Sept 2026 (T+90)
- 30,451 sharesShareKRXDART:20260611000018Canonical exit: 9 Sept 2026 (T+90)
- 4,000 sharesShareKRXDART:20260611000012Canonical exit: 9 Sept 2026 (T+90)
- 26,300 shares@ ₩1,785.80160.18% mcap47.3% of flowShareKRXDART:20260408000069Canonical exit: 5 Jul 2026 (T+90)
- 30,000 shares@ ₩1,708.44230.20% mcap52.7% of flowShareKRXDART:20260318000017Canonical exit: 10 Jun 2026 (T+90)
25 of 75 declarations
About Genolution Inc.
제놀루션 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative solutions for the medical sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
